Gemcitabine for Advanced Endometrial Cancer

• DOI: 10.1097/igc.0b013e31824a33a2
• Publication Date: 2012-05-24T15:21:31Z
• Authors: Rachel Nicole Gri...; Christina Adaniel; David M. Hyman; Weining Ma; Alexia Iasonos; Carol Aghajanian; Jason Konner
• Keywords: Carcinosarcoma; Uterine cancer

<h3>Background</h3> Gemcitabine is active in several gynecologic malignancies including ovarian cancer, cervical and uterine leiomyosarcoma. It has been used an off-label setting for the treatment of advanced endometrial despite lack published data showing efficacy. We performed a retrospective study to determine progression-free survival response rate cancer patients treated with gemcitabine at Memorial Sloan-Kettering Cancer Center. <h3>Methods</h3> Eligible had histologically confirmed (stage IV or recurrent) that was single-agent Center between 1999 2009. Response therapy determined by review computed tomography imaging Evaluation Criteria Solid Tumors 1.1 criteria. <h3>Results</h3> Forty-six were included analysis. Median age 66 years (range, 52–87 years). All previously chemotherapy. The median number prior lines chemotherapy 2 1–8). dose administered 800 mg/m² infused on days 1 8 21-day cycle. Predominant histology endometrioid (48%, n = 22) followed serous (35%, 16), clear cell (15%, 7), undifferentiated (2%, 1). Overall 10.9% (95% confidence interval, 1.9%–19.9%); 5 (11%) achieved partial response. Thirteen (28%) displayed stable disease lasting least 3 months. Of note, (71%) 7 (n 5). 3.0 months 2.1–3.3 months). Nonhematologic grades 4 toxicities rare. Ten (22%) granulocyte colony-stimulating factor during treatment. Grade thrombocytopenia seen (9%). There no cases grade thrombocytopenia. <h3>Conclusions</h3> In mixed population well tolerated showed modest activity. Patients appeared have greater likelihood benefit.